ARDX vs MRNA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARDX and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARDX and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Ardelyx is a commercial-stage biopharmaceutical company whose business rests on one active molecule, tenapanor, marketed under two brand names for two conditions. IBSRELA treats irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH controls elevated serum phosphorus (hyperphosphatemia) in adults with chronic kidney disease on dialysis who respond inadequately to, or cannot tolerate, phosphate binders. Ardelyx also earns royalties and collaboration revenue from partners who sell tenapanor in markets like Japan and China.

Full ARDX guide

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ARDX drivers: IBSRELA growth engine; XPHOZAH and the reimbursement path.
• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Ardelyx's revenue depends almost entirely on one molecule, tenapanor, so any efficacy, safety, manufacturing, or patent challenge would hit the whole business. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARDX if you believe its drivers more; MRNA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARDX and MRNA guides.

ARDX. Figures are approximate and tied to the asOf date; verify live numbers before acting. As a two-product specialty biopharma concentrated in one molecule, Ardelyx is valued mainly on IBSRELA's growth trajectory and on how XPHOZAH's Medicare reimbursement resolves, not on a stable earnings multiple. Small changes in prescription trends, payer coverage, or trial outcomes can move the investment case materially, so headline revenue growth should be weighed against those binary policy and pipeline factors.

MRNA. MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

Headline figures (approximate, Jul 2026): ARDX shows ibsrela revenue (q1 2026) approximately $70 million, up about 58% year over year, ibsrela full-year 2026 guidance approximately $410 million to $430 million, xphozah revenue (q1 2026) approximately $23 million, with a US reimbursement overhang, profitability moving toward operating leverage as revenue scales; verify latest net income and cash position; MRNA shows market cap ~$20 billion, q1 2026 revenue ~$400 million, q1 2026 net loss ~$1.3 billion (incl. ~$878M legal charge), 2026 revenue growth guidance up to ~10%.

ARDX and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARDX and MRNA exposure against your real portfolio. It is not an investment adviser.